Financial Data and Key Metrics Changes - The company expects to transition its business model post-Jakafi, aiming for a five-year compound annual growth rate (CAGR) of 15%-20% with multiple products projected to generate over $1 billion in revenue each [6][20][21] - Jakafi sales are anticipated to be preserved with the launch of a once-daily formulation, potentially maintaining nearly $750 million in sales through 2029 [7][8] Business Line Data and Key Metrics Changes - The core business, excluding Jakafi, is projected to grow significantly, potentially matching Jakafi's revenue by 2029 [4][6] - Opzelura finished the year with approximately $650 million in sales, with expectations of a 10% CAGR, potentially doubling by 2030 [21][22] - The company has seven late-stage pipeline projects that could enhance its core business in hematology, oncology, and immunology [4][6] Market Data and Key Metrics Changes - The U.S. market is experiencing a shift from topical corticosteroids to nonsteroidal topicals, with Opzelura positioned to benefit from this trend [21][22] - The company anticipates approval for Opzelura in moderate atopic dermatitis in Europe by mid to late 2026, which could significantly drive growth [23][24] Company Strategy and Development Direction - The company aims to establish a targeted therapy for every patient with myeloproliferative neoplasms (MPNs) by the end of the decade, with a focus on executing clinical trials efficiently [18][19] - Business development efforts will focus on extending the core in hematology, oncology, and immunology [4][61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the pipeline's potential, emphasizing the importance of execution and the favorable positioning of their products in competitive markets [6][20] - The company is aware of competition but believes it has a strong lead in several therapeutic areas, particularly with its G12D inhibitor and other oncology programs [20][55] Other Important Information - The company is preparing for the submission of povorcitinib in the U.S. in early 2026, with expectations of a launch by late 2026 or early 2027 [31][32] - The company has a robust consumer campaign for vitiligo treatment, aiming to increase diagnosis and treatment rates [26] Q&A Session Summary Question: Can you discuss the growth potential of Opzelura? - Opzelura is expected to grow at a 10% CAGR, potentially reaching $1.3 billion by 2030, driven by increased market penetration and new indications [21][22] Question: What is the timeline for the submission of povorcitinib? - The submission for povorcitinib is planned for early 2026, with potential approval by late 2026 or early 2027 [31][32] Question: How does the company view its competitive positioning in the market? - The company believes it has a strong lead in the market, particularly with its G12D inhibitor, and is focused on executing its clinical trials effectively [20][55] Question: What are the expectations for the upcoming data presentations? - The company is preparing to present data at ASH, which will provide further insights into its pipeline and product efficacy [62]